The global formulation development outsourcing market size accounted for USD 43.08 billion in 2024, grew to USD 46.23 billion in 2025 and is projected to surpass around USD 87.31 billion by 2034, representing a healthy CAGR of 7.32% between 2024 and 2034.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Formulation Development Outsourcing Market
5.1. COVID-19 Landscape: Formulation Development Outsourcing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Formulation Development Outsourcing Market, By Service
8.1. Formulation Development Outsourcing Market, by Service, 2024-2034
8.1.1. Preformulation
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Formulation Development
8.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Formulation Development Outsourcing Market, By Formulation
9.1. Formulation Development Outsourcing Market, by Formulation, 2024-2034
9.1.1. Topical
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Oral
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Injectable
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Formulation Development Outsourcing Market, By Therapeutic Area
10.1. Formulation Development Outsourcing Market, by Therapeutic Area, 2024-2034
10.1.1. Oncology
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Infectious Disease
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Respiratory
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Cardiovascular
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Neurology
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. Hematology
10.1.6.1. Market Revenue and Forecast (2021-2034)
10.1.7. Dermatology
10.1.7.1. Market Revenue and Forecast (2021-2034)
10.1.8. Others
10.1.8.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Formulation Development Outsourcing Market, By End-User
11.1. Formulation Development Outsourcing Market, by End-User, 2024-2034
11.1.1. Pharmaceutical Industries
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Research and Academic Institutions
11.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 12. Global Formulation Development Outsourcing Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Service (2021-2034)
12.1.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.1.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.1.4. Market Revenue and Forecast, by End-User (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Service (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.1.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Service (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.1.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Service (2021-2034)
12.2.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.2.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.2.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Service (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.2.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Service (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.2.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Service (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.2.7.4. Market Revenue and Forecast, by End-User (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Service (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.2.8.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Service (2021-2034)
12.3.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.3.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.3.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Service (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.3.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Service (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.3.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Service (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.3.7.4. Market Revenue and Forecast, by End-User (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Service (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.3.8.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Service (2021-2034)
12.4.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.4.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.4.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Service (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.4.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Service (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.4.6.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Service (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.4.7.4. Market Revenue and Forecast, by End-User (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Service (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.4.8.4. Market Revenue and Forecast, by End-User (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Service (2021-2034)
12.5.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.5.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Service (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.5.5.4. Market Revenue and Forecast, by End-User (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Service (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Formulation (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
12.5.6.4. Market Revenue and Forecast, by End-User (2021-2034)
Chapter 13. Company Profiles
13.1. SGS S.A.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eurofins Scientific SE
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Element
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Labcorp
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Thermo Fisher Scientific, Inc. (Patheon)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Intertek Group plc
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Recipharm
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Lonza
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Charles River Laboratories International, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Catalent Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample